Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), announces its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
Read the full article: Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies //
Source: https://www.prnewswire.com/news-releases/orna-therapeutics-announces-strategic-acquisition-of-renagade-therapeutics-to-solidify-leadership-in-circular-rna-therapies-302153347.html